Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Duke University
- Target Recruit Count
- 94
- Registration Number
- NCT00131963
- Locations
- 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Lymphoblastic Leukemia, Acute
- Interventions
- First Posted Date
- 2005-08-17
- Last Posted Date
- 2008-11-14
- Lead Sponsor
- Japan Adult Leukemia Study Group
- Target Recruit Count
- 120
- Registration Number
- NCT00131053
- Locations
- 🇯🇵
Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Lymphoblastic Leukemia, Acute
- Interventions
- First Posted Date
- 2005-08-17
- Last Posted Date
- 2008-11-14
- Lead Sponsor
- Japan Adult Leukemia Study Group
- Target Recruit Count
- 240
- Registration Number
- NCT00131027
- Locations
- 🇯🇵
Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2008-11-14
- Lead Sponsor
- Japan Adult Leukemia Study Group
- Target Recruit Count
- 100
- Registration Number
- NCT00130195
- Locations
- 🇯🇵
Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 1289
- Registration Number
- NCT00129922
- Locations
- 🇪🇸
Hospital del Mar, Barcelona, Spain
🇪🇸Hospital General Universitario de Elche, Elche, Alicante, Spain
🇪🇸Hospital Universitario Puerto Real, Puerto Real, Cádiz, Spain
EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 1384
- Registration Number
- NCT00129935
- Locations
- 🇪🇸
Hospital Arquitecto Marcide, Ferrol, A Coruña, Spain
🇪🇸Hospital General Universitario de Elche, Elche, Alicante, Spain
🇪🇸Hospital General Universitario de Elda, Elda, Alicante, Spain
FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 1925
- Registration Number
- NCT00129389
- Locations
- 🇪🇸
Hospital General de Elda, Elda, Alicante, Spain
🇪🇸Consorci Sanitari Terrassa, Terrassa, Barcelona, Spain
🇪🇸Hospital Clínico Universitario de Salamanca, Salamanca, Spain
Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 63
- Registration Number
- NCT00129376
- Locations
- 🇪🇸
Hospital General Universitario de Alicante, Alicante, Spain
🇪🇸Fundación Jiménez Díaz, Madrid, Spain
🇪🇸Hospital de la Ribera, Alcira, Valencia, Spain
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
- Conditions
- Burkitt LymphomaNon-Hodgkins LymphomaAtypical Burkitt Lymphoma
- Interventions
- First Posted Date
- 2005-08-03
- Last Posted Date
- 2013-05-23
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT00126191
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2005-07-27
- Last Posted Date
- 2010-02-26
- Lead Sponsor
- Amgen
- Registration Number
- NCT00124111
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.